A science-first directory that separates approved therapeutics from research-only compounds, and makes the evidence boundary obvious.
Educational only, not medical advice.
How this hub is organized
We do not treat “peptide” as a single credibility bucket. Some peptides are FDA-approved drugs with labeled indications. Others are research compounds with little or no human efficacy data. Those are different evidence situations, and this hub keeps them separate.
What we prioritize
Approval status, study quality, and source transparency
What we avoid
Hypey protocol talk, miracle language, and evidence inflation
Best next step
Start with labels, trials, and PubMed when a claim matters
These pages cover peptides that have an actual regulatory approval history, but still require indication-specific reading.
Ozempic, Wegovy, Rybelsus
Large clinical program with labeled indications and major cardiovascular outcomes data.
EGRIFTA category
Approved in a specific HIV-associated lipodystrophy setting, not for broad physique or wellness claims.
Labeled therapies only
We will add new pages when we can clearly ground them in labels, trial programs, and primary sources.
These pages exist to summarize literature and regulatory status, not to imply approved human use.
Body Protection Compound
Mostly animal and preclinical literature, with major human evidence gaps.
Thymosin beta-4 fragment
Commonly discussed online, but far from the evidence bar of approved therapeutics.
Only where context is clear
We would rather publish fewer pages than blur the line between research compounds and approved medications.
For approved drugs
Start with FDA labels, pivotal trial publications, and major safety communications.
For research compounds
Check whether the literature is animal-only, early-stage, uncontrolled, or absent in humans.
For regulatory context
Use enforcement letters, shortage notices, and formal policy updates instead of vendor claims.
Jabbit is a tracking and organization product. The editorial standard here is simple: help readers understand labels, evidence, and uncertainty without turning the category into marketing theater.